Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study
- Resource Type
- Authors
- Sheng Liu; Xiaoqiang Tong; Hao Hu; Yancu Hertzanu; Zheng-Qiang Yang; Hai-Bin Shi; Xiao-Quan Xu; Xiaoran Long; Zhenhua Duan
- Source
- PLoS ONE, Vol 10, Iss 2, p e0117168 (2015)
PLoS ONE
- Subject
- Male
Niacinamide
Sorafenib
Oncology
medicine.medical_specialty
Carcinoma, Hepatocellular
lcsh:Medicine
Antineoplastic Agents
Internal medicine
Humans
Medicine
Chemoembolization, Therapeutic
Propensity Score
Adverse effect
lcsh:Science
neoplasms
Survival analysis
Aged
Retrospective Studies
Geriatrics
Multidisciplinary
business.industry
Phenylurea Compounds
Liver Neoplasms
lcsh:R
Age Factors
Retrospective cohort study
Patient survival
Arteries
Middle Aged
medicine.disease
Survival Analysis
humanities
digestive system diseases
Surgery
Treatment Outcome
Hepatocellular carcinoma
Propensity score matching
Female
lcsh:Q
Safety
business
Research Article
medicine.drug
- Language
- English
- ISSN
- 1932-6203
Aims This retrospective study was carried out to compare the outcomes between elderly (≥70 years of age) and nonelderly patients (